Investment Rating - The investment rating for the company is "Buy" [8][10]. Core Views - The company's overall performance is stable, with a slight fluctuation in Q4. In 2024, the company achieved revenue of 1.15 billion yuan, a year-on-year increase of 0.20%, with domestic revenue at 759 million yuan (down 6.16%) and international revenue at 372 million yuan (up 14.87%). The net profit attributable to the parent company was 345 million yuan, reflecting a year-on-year increase of 5.12% [8]. - The in vitro diagnostic (IVD) segment is experiencing rapid growth, with revenue reaching 911 million yuan in 2024, a year-on-year increase of 9.96%. The gross margin for this segment is 69.68%, up 5.71 percentage points year-on-year [8]. - The treatment and rehabilitation business saw a decline, with revenue of 220 million yuan in 2024, down 27.68% year-on-year. However, the company is enhancing its marketing efforts, particularly in e-commerce, to boost sales in this segment [8]. Summary by Sections Financial Performance - In 2024, the company reported a main business revenue of 1.15 billion yuan, with a gross margin of 67.21% and a net profit margin of 29.87% [8]. - The projected net profits for 2025, 2026, and 2027 are 407 million yuan, 472 million yuan, and 537 million yuan, respectively, with corresponding EPS of 0.95 yuan, 1.10 yuan, and 1.25 yuan [8][9]. Business Segments - The IVD segment is expected to maintain strong growth due to new product launches and technological advancements [8]. - The treatment and rehabilitation segment is anticipated to recover as the company improves its product lineup and marketing strategies [8]. Valuation Metrics - The company is projected to have a PE ratio of 14.41 for 2025, decreasing to 10.91 by 2027, indicating a favorable valuation trend [8][9].

Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company has shown strong performance in home products and steady growth overseas, with a revenue forecast adjustment for 2024 and an increase in gross margin expectations [3][11] - The company is expected to achieve EPS of 0.91, 1.06, and 1.18 yuan for the years 2025, 2026, and 2027 respectively, with a target price set at 17.29 yuan based on a 19x PE for 2025 [3][7] Financial Summary - The company reported a revenue of 1,146 million yuan in 2023, with a slight increase to 1,148 million yuan in 2024, and projected revenues of 1,294 million yuan, 1,465 million yuan, and 1,650 million yuan for 2025, 2026, and 2027 respectively, reflecting growth rates of 12.8%, 13.2%, and 12.6% [5][11] - The gross margin is expected to improve from 63.0% in 2023 to 67.2% in 2024, with a slight decline projected thereafter [5][11] - The net profit attributable to the parent company is forecasted to grow from 329 million yuan in 2023 to 507 million yuan in 2027, with growth rates of 30.7%, 5.1%, 12.9%, 16.9%, and 11.2% for the respective years [5][11] - The company’s operating profit is projected to increase from 345 million yuan in 2023 to 547 million yuan in 2027, with growth rates of 34.6%, 9.5%, 9.3%, 19.3%, and 11.1% [5][11] - The company’s net profit margin is expected to rise from 28.7% in 2023 to 30.7% in 2027 [5][11]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company's profitability is steadily improving, with rapid growth in testing and home products [5] - The company focuses on in vitro diagnostics, treatment, and rehabilitation, with significant revenue growth in testing reagents [6] - The company has a competitive advantage in the IVD sector and is experiencing rapid growth in its treatment and rehabilitation business [6] Financial Performance Summary - For 2024, the company achieved revenue of 1.148 billion yuan, a year-on-year increase of 0.20%, and a net profit attributable to shareholders of 345 million yuan, up 5.12% year-on-year [6] - The company expects revenues of 1.322 billion yuan in 2025, with a year-on-year growth rate of 15.14% [5] - The gross margin for 2024 was 67.21%, an increase of 4.21 percentage points year-on-year, while the net margin was 29.87%, up 1.29 percentage points year-on-year [6] Revenue and Profit Forecast - Revenue forecasts for 2025-2027 are 13.22 billion yuan, 15.20 billion yuan, and 17.44 billion yuan, with respective growth rates of 15.14%, 14.99%, and 14.74% [5] - Net profit forecasts for the same period are 396 million yuan, 455 million yuan, and 525 million yuan, with growth rates of 14.57%, 15.05%, and 15.30% [5] Valuation Metrics - The current price-to-earnings (P/E) ratios for 2025, 2026, and 2027 are projected to be 15x, 13x, and 11x respectively [5]

Core Viewpoint - The company has received IVDR CE certification from T V South German Group for 13 electrochemical luminescence reagent products, enhancing its competitiveness in the EU market [1] Group 1: Certification Details - The certified products include assays for anti-thyroglobulin antibody, C-peptide, total triiodothyronine, total thyroxine, thyroxine-binding globulin, free triiodothyronine, free thyroxine, estradiol, follicle-stimulating hormone, luteinizing hormone, prolactin, and testosterone [1] - These products are classified as Class B and have a validity period until June 23, 2029 [1] - The company has a total of 20 electrochemical luminescence reagent products that have obtained IVDR CE certification to date [1] Group 2: Market Impact - The new IVDR regulations replace the previous IVDD directive, governing in vitro diagnostic medical devices in the EU market [1] - The certification allows the company’s products to enter the EU market, which is expected to positively impact the company's future operations [1]

Policy Developments - The National Healthcare Security Administration has established data working groups across all regions, with the aim of enhancing data governance and transparency in healthcare funding [2] Drug and Device Approvals - Jiangsu Tianshili submitted a listing application for the new drug PXT3003, intended for the treatment of Charcot-Marie-Tooth disease type 1A [4] Capital Markets - Ruijian Pharmaceutical completed nearly 100 million RMB in B+ round financing, bringing total financing to over 200 million RMB in less than six months [6] - Weichan Medical announced the completion of several million RMB in angel round financing, aimed at accelerating product development and market entry [7] - Novartis plans to invest $23 billion in the U.S. over the next five years to enhance production capabilities and ensure the domestic supply of critical medications [8] Industry Events - Boya Bio disclosed plans to sell 80% of its subsidiary, Boya Xinha, to focus on its core blood products business, with an initial listing price of 213 million RMB [10] Financial Reports - Pumen Technology reported a revenue of 1.148 billion RMB for 2024, with a net profit of 345 million RMB, reflecting a 5.12% increase [12] - Huaxi Biotechnology's revenue for 2024 was 5.371 billion RMB, down 11.61%, with a net profit of 174 million RMB, down 70.59% [13] - Watson Bio reported a revenue of 2.821 billion RMB for 2024, down 31.41%, with a net profit of 142 million RMB, down 66.10% [14] - Innovation Medical reported a revenue of 816 million RMB for 2024, with a net loss of 93.95 million RMB [15] - People's Tongtai reported a revenue of 10.048 billion RMB for 2024, down 3.29%, with a net profit of 213 million RMB, down 27% [16] - Haizike reported a revenue of 3.721 billion RMB for 2024, with a net profit of 395 million RMB, up 34% [17] - Hainan Haiyao reported a revenue of approximately 999 million RMB for 2024, down 33%, with a net loss of 1.525 billion RMB [18] - Wantai Bio reported a revenue of approximately 2.245 billion RMB for 2024, down 59.25%, with a net profit of 106 million RMB, down 91.49% [19] Public Opinion Alerts - Xinghao Pharmaceutical announced the resignation of director Li Huiqu due to personal reasons, effective April 11, 2025 [21] - Zhaoyan New Drug acknowledged unusual fluctuations in its stock price, linked to a recent FDA plan that may impact the industry [23]

Policy Developments - The National Healthcare Security Administration has established data working groups across all regions to enhance data governance and transparency in healthcare funding [2] - These groups will regularly publish data to improve the quality of healthcare services and ensure the safety of healthcare funds [2] Drug and Device Approvals - Jiangsu Tian Shi Li has submitted a listing application for a new drug PXT3003, aimed at treating Charcot-Marie-Tooth disease type 1A [3] Capital Markets - Ruijian Pharmaceutical has completed nearly 100 million RMB in B+ round financing, bringing total financing to over 200 million RMB in less than six months [4] - Weichan Medical has announced the completion of several million RMB in angel round financing to accelerate product development and innovation [5] - Novartis plans to invest $23 billion in the U.S. over the next five years to enhance production capabilities and ensure key drugs are manufactured domestically [6] Industry Events - Boya Biotechnology intends to sell 80% of its subsidiary, Jiangxi Boya Xinhao Pharmaceutical, to focus on its core blood products business [7] Financial Reports - Pumen Technology reported a revenue of 1.148 billion RMB for 2024, with a net profit of 345 million RMB, reflecting a 5.12% increase [8] - Huaxi Biotechnology's revenue for 2024 was 5.371 billion RMB, down 11.61%, with a net profit of 174 million RMB, down 70.59% [9] - Watson Bio reported a revenue of 2.821 billion RMB for 2024, down 31.41%, with a net profit of 142 million RMB, down 66.10% [10] - Innovation Medical reported a revenue of 816 million RMB for 2024, with a net loss of 93.95 million RMB [11] - Renmin Tongtai achieved a revenue of 10.048 billion RMB for 2024, down 3.29%, with a net profit of 213 million RMB, down 27% [12] - Haishi Pharmaceutical reported a revenue of approximately 999 million RMB for 2024, down 33%, with a net loss of 1.525 billion RMB [14] - Wantai Biological reported a revenue of approximately 2.245 billion RMB for 2024, down 59.25%, with a net profit of 106 million RMB, down 91.49% [15] - Haishi Pharmaceutical reported a net profit of 395 million RMB for 2024, up 34% [13] Public Sentiment Alerts - Xinghao Pharmaceutical announced the resignation of director Li Huiqu due to personal reasons [16] - Zhaoyan Pharmaceutical acknowledged unusual fluctuations in its stock price, linked to FDA plans that may impact the industry [17]

Investment Rating - The report maintains a "Buy" rating for the company [3][5][17] Core Viewpoints - The company achieved a revenue of 1.148 billion yuan in 2024, a slight increase of 0.20% year-on-year, with a net profit of 345 million yuan, up 5.12% [1][12] - The company is focusing on strengthening its IVD (In Vitro Diagnostics) and clinical medical business while actively expanding into the consumer health sector, including skin aesthetics and consumer health products [3][16][17] - The report anticipates revenue growth for the years 2025 to 2027, projecting revenues of 1.262 billion yuan, 1.372 billion yuan, and 1.489 billion yuan respectively, with net profits of 389 million yuan, 433 million yuan, and 485 million yuan [3][4][17] Financial Summary - In 2024, the company's revenue was 1,148 million yuan, with a growth rate of 0.20%. The projected revenues for 2025, 2026, and 2027 are 1,262 million yuan, 1,372 million yuan, and 1,489 million yuan respectively, reflecting growth rates of 9.91%, 8.71%, and 8.55% [4][18] - The net profit for 2024 was 345 million yuan, with expected growth rates of 12.65%, 11.31%, and 12.01% for the following years [4][18] - The gross margin for 2024 was reported at 67.21%, an increase of 1.40 percentage points, driven by a higher proportion of high-margin IVD reagents [15][18] Product Performance - The IVD segment generated 911 million yuan in revenue, accounting for 79.39% of total revenue, with a year-on-year increase of 9.96%. The revenue from diagnostic reagents was 652 million yuan, up 25.73% [2][13] - The therapeutic and rehabilitation segment saw a decline, with revenues of 220 million yuan, down 27.68%. However, home product sales increased by 36.29% due to enhanced marketing efforts [2][13] - The company reported a significant increase in sales volume for diagnostic reagents, attributed to the prior installation of equipment boosting reagent sales [2][13] Regional Performance - Domestic revenue was 759 million yuan, accounting for 66.13% of total revenue, down 6.16% year-on-year. In contrast, overseas revenue reached 372 million yuan, representing 32.43% of total revenue, with a year-on-year increase of 14.87% [2][13]

Group 1: U.S. CPI and Tariff Impact - The U.S. CPI growth rate in March was lower than expected, indicating a cooling trend, with the impact of tariffs on inflation not yet significant [1] - Despite a 90-day tariff suspension announced by Trump, various tariff measures remain in effect, potentially raising the PCE deflator by approximately 1.2% this year [1] - The market's pricing of "stagnation" is considered adequate, while the pricing of "inflation" may be insufficient, with the Federal Reserve likely to cut rates up to two times this year [1] Group 2: Price Data and Tariff Effects - In March 2025, the CPI remained weak, aligning with market expectations, while the PPI was slightly below expectations, driven by falling international oil prices and weak domestic construction activity [2] - The additional tariffs on China have reached a rate of 20%, negatively impacting domestic exports and PPI, estimated to contribute a 0.13 percentage point decline in PPI [2] - The anticipated impact of U.S. tariffs on PPI could range from a 1.8% to 3.2% decline, while China's counter-tariffs may raise CPI by about 0.1 percentage points [2] Group 3: Banking and Financial Products - In March 2025, the issuance of bank wealth management products increased, with a total of 2,964 products launched [4] - The average annualized yield for pure debt and non-pure debt fixed-income products rose to 2.35% and 2.10%, respectively, reflecting a recovery from the previous month [4] - The total scale of bank wealth management products reached 29.32 trillion yuan, showing a seasonal decline but supported by improved product yields [4] Group 4: Tariff Policies and Economic Outlook - Trump's tariff policies are compared to historical protectionist measures, with expectations for negotiations on reciprocal tariffs to conclude in mid-2025, although U.S.-China trade talks may take longer [5] - The implementation of "reciprocal tariffs" has triggered a global risk-averse capital flow, leading to a significant drop in risk assets and a rally in safe-haven assets [6] - The bond market is expected to perform well, with dividend-paying assets becoming a core safe haven amid tariff-related uncertainties [6] Group 5: Consumer Finance ABS - The growth in consumer loans has led to a significant increase in the issuance of consumer finance ABS in early 2025, with improved asset quality and attractive yield spreads compared to non-financial credit bonds [7] - The focus is on the investment opportunities in consumer finance ABS, particularly in bank-affiliated consumer finance subsidiaries and state-owned enterprise trust products [7]

公司2024年年度股东大会的会议通知详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《深圳普门科技股份有限公司关于召开2024年年度股东大会的通知》（公告编号：2025-029）。 （二十七）审议通过《关于会计政策变更的议案》 根据财政部于2024年12月颁布的《企业会计准测解释第18号》（财会〔2024〕24号）、于2024年3月发 布的《企业会计准则应用指南汇编2024》的规定，董事会同意公司进行相应的会计政策变更，并自2024 年1月1日起执行。本次会计政策变更不会对公司财务状况、经营成果和现金流量产生重大影响，亦不存 在损害公司及股东利益的情况。 本议案已经公司董事会审计委员会审议通过，并同意提交董事会审议。 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的《深圳普门科技股份有限公 司关于会计政策变更的公告》（公告编号：2025-030）。 登录新浪财经APP 搜索【信披】查看更多考评等级 董事会同意于2025年5月7日召开公司2024年年度股东大会，本次股东大会将采用现场投票及网络投票相 结合的表决方式召开。 表决结果：9票同意、0票反对、0 ...

一、主要会计数据和财务指标 10派2.82元(含税) 前十大流通股东累计持有： 24708.46万股，累计占流通股比： 57.67%，较上期变化： -273.91万股。 | 持有数量(万股) 名称 | | 占总股本比 | 增减情况 | | --- | --- | --- | --- | | | | 例(%) | (万股) | | 刘先成 | 12590.09 | 29.38 | 不变 | | 胡明龙 | 2102.44 | 4.91 | 不变 | | 中国工商银行股份有限公司-富国天惠精选成长混合型证 | | | | | 券投资基金(LOF) | 2000.00 | 4.67 | 新进 | | 曾映 | 1966.90 | 4.59 | 不变 | | 厦门瀚钰投资咨询合伙企业(有限合伙) | 1434.67 | 3.35 | 不变 | | 基本养老保险基金一六零二二组合 | 1300.18 | 3.03 | 不变 | | 徐岩 | 1254.20 | 2.93 | 0.42 | | 厦门乔川投资合伙企业(有限合伙) | 1108.41 | 2.59 | 不变 | | 全国社保基金四零三组合 | 475.86 ...